Merck & Co., Inc. Stock Forecast, Price & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, MRK stock has increased by 4.7% and is now trading at $82.95.
View which stocks have been most impacted by COVID-19.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Tuesday, October 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) released its quarterly earnings results on Friday, July, 31st. The company reported $1.37 EPS for the quarter, topping the Zacks' consensus estimate of $1.14 by $0.23. The firm had revenue of $10.87 billion for the quarter, compared to analysts' expectations of $10.52 billion. Merck & Co., Inc. had a return on equity of 52.94% and a net margin of 22.20%. The business's revenue was down 7.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.30 EPS.
View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. declared a quarterly dividend on Wednesday, July 29th. Shareholders of record on Tuesday, September 15th will be paid a dividend of $0.61 per share on Wednesday, October 7th. This represents a $2.44 annualized dividend and a yield of 2.94%. The ex-dividend date is Monday, September 14th.
View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its Board of Directors has initiated a share buyback program on Thursday, October 25th 2018, which permits the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase up to 5.1% of its stock through open market purchases. Stock buyback programs are generally a sign that the company's management believes its stock is undervalued.

Merck & Co., Inc. updated its FY20 earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of $5.63-5.78 for the period, compared to the Thomson Reuters consensus estimate of $5.31. The company issued revenue guidance of $47.2-48.7 billion, compared to the consensus revenue estimate of $47.33 billion.

14 brokerages have issued 1-year target prices for Merck & Co., Inc.'s shares. Their forecasts range from $88.00 to $105.00. On average, they expect Merck & Co., Inc.'s share price to reach $94.07 in the next year. This suggests a possible upside of 13.4% from the stock's current price.
View analysts' price targets for Merck & Co., Inc..

News stories about MRK stock have trended somewhat positive on Wednesday, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merck & Co., Inc. earned a news impact score of 2.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a drop in short interest in September. As of September 15th, there was short interest totaling 10,970,000 shares, a drop of 9.4% from the August 31st total of 12,110,000 shares. Based on an average trading volume of 7,950,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 0.4% of the shares of the company are sold short.
View Merck & Co., Inc.'s Short Interest.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Horizon Therapeutics (HZNP), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Mylan (MYL), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $82.95.

Merck & Co., Inc. has a market capitalization of $209.80 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]